IN THE CLAIMS

   Please withdraw claims 1-39 and 46-49 as described below pursuant to the Restriction Requirement imposed in the parent application no. 09/501,149:

1. (Withdrawn).

2. (Withdrawn).

3. (Withdrawn).

4. (Withdrawn).

5. (Withdrawn).

6. (Withdrawn).

7. (Withdrawn).

8. (Withdrawn).

9. (Withdrawn).

10. (Withdrawn).

11. (Withdrawn).

12. (Withdrawn).

13. (Withdrawn).

14. (Withdrawn).

15. (Withdrawn).

16. (Withdrawn).

17. (Withdrawn).

18. (Withdrawn).

19. (Withdrawn).

20. (Withdrawn).

21. (Withdrawn).

22. (Withdrawn).

23. (Withdrawn).

24. (Withdrawn).

25. (Withdrawn).

26. (Withdrawn).

27. (Withdrawn).

28. (Withdrawn)

29. (Withdrawn).

30. (Withdrawn).

31. (Withdrawn).

32. (Withdrawn).

33. (Withdrawn).

34. (Withdrawn).

35. (Withdrawn).

36. (Withdrawn).

37. (Withdrawn).

38. (Withdrawn).

39. (Withdrawn).

40. (Currently amended) A method suitable for determining the effect of a new or known drug on the CNS system of a patient, comprising: selecting at least one patient administering the drug to the patient, obtaining the patient's post administration neurophysiologic information, analyzing the patient's post administration neurophysiologic information to determine the effect of the drug on the CNS system of the patient.

41. (Currently amended) A method according to claim 40, wherein analyzing step includes comparing the patient's neurophysiologic information with neurophysiologic information obtained from a reference population of individuals to produce a similarities profile for the patient.

42. (Currently amended) A method according to claim 41, wherein the similarities profile is used to determine the effect of the drug.

43. (Currently amended) A method according to claim 40, wherein pre-administration neurophysiologic information is obtained from the patient.

44. (Currently amended) A method according to claim 43, wherein the pre-administration neurophysiologic information is also compared to the neurophysiologic information from the reference population.